Sp455
FUNCTIONAL AND MOTILITY DISORDERS
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
This session brings together UEG member experts to provide a broad overview highlighting the best of abstracts presented at UEG Week 2022.
This session brings together UEG member experts to provide a broad overview highlighting the best of abstracts presented at UEG Week 2022.
Presenter
Nottingham Digestive Diseases Centre
Tracks
Related Products
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
AGA Irritable Bowel Syndrome: Pathophysiology
SOCIETY: AGA
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
